NCT07417501 2026-02-18
Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification
Tongji Hospital
Phase 2 Not yet recruiting
Clinical Trials
3 trialsNCT03477175 2025-01-07
Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials
Eisai Inc.
Phase 2 Completed
NCT05740215 2023-02-22
Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
Shandong New Time Pharmaceutical Co., LTD
Phase 1/2 Unknown